3624 related articles for article (PubMed ID: 29968072)
1. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
2. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Bartha E; Solti I; Kereskai L; Lantos J; Plozer E; Magyar K; Szabados E; Kálai T; Hideg K; Halmosi R; Sumegi B; Toth K
Cardiovasc Res; 2009 Aug; 83(3):501-10. PubMed ID: 19443425
[TBL] [Abstract][Full Text] [Related]
4. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.
Kaplan J; O'Connor M; Hake PW; Zingarelli B
Shock; 2005 Mar; 23(3):233-8. PubMed ID: 15718920
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Qin WD; Liu GL; Wang J; Wang H; Zhang JN; Zhang F; Ma Y; Ji XY; Li C; Zhang MX
Oncotarget; 2016 Jun; 7(24):35618-35631. PubMed ID: 27027354
[TBL] [Abstract][Full Text] [Related]
7. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.
Evgenov OV; Liaudet L
Curr Vasc Pharmacol; 2005 Jul; 3(3):293-9. PubMed ID: 16026325
[TBL] [Abstract][Full Text] [Related]
8. Neuronal trauma model: in search of Thanatos.
Cole K; Perez-Polo JR
Int J Dev Neurosci; 2004 Nov; 22(7):485-96. PubMed ID: 15465278
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Skaper SD
Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
[TBL] [Abstract][Full Text] [Related]
11. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.
Halmosi R; Berente Z; Osz E; Toth K; Literati-Nagy P; Sumegi B
Mol Pharmacol; 2001 Jun; 59(6):1497-505. PubMed ID: 11353811
[TBL] [Abstract][Full Text] [Related]
12. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.
Hans CP; Zerfaoui M; Naura AS; Catling A; Boulares AH
Cardiovasc Res; 2008 Jun; 78(3):429-39. PubMed ID: 18245064
[TBL] [Abstract][Full Text] [Related]
15. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
Mathews MT; Berk BC
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):711-7. PubMed ID: 18239155
[TBL] [Abstract][Full Text] [Related]
16. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
Beneke S; Diefenbach J; Bürkle A
Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.
Kaur G; Singh N; Lingeshwar P; Siddiqui HH; Hanif K
Pulm Pharmacol Ther; 2015 Feb; 30():66-79. PubMed ID: 25481773
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Qin WD; Wei SJ; Wang XP; Wang J; Wang WK; Liu F; Gong L; Yan F; Zhang Y; Zhang M
Biochim Biophys Acta; 2013 Jan; 1833(1):59-68. PubMed ID: 23085506
[TBL] [Abstract][Full Text] [Related]
20. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
